File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Article: The Hong Kong consensus statements on unresectable hepatocellular carcinoma: narrative review and update for 2021

TitleThe Hong Kong consensus statements on unresectable hepatocellular carcinoma: narrative review and update for 2021
Authors
Issue Date1-Jun-2023
PublisherAME Publishing
Citation
Hepatobiliary Surgery and Nutrition, 2023, v. 12, n. 3, p. 366-385 How to Cite?
Abstract

Background and Objective: Hong Kong, like many parts of Asia, faces a high burden of hepatocellular carcinoma (HCC) caused by high endemic rates of hepatitis B virus infection. Hong Kong clinicians have developed a high level of expertise in HCC treatment across surgical, transarterial, ablative, radiotherapeutic and systemic modalities. This publication summarizes the latest evidence-based recommendations on how these modalities should be used.

Methods: In two meetings held in 2020, a multidisciplinary panel of surgeons, oncologists and interventional radiologists performed a narrative review of evidence on the management of HCC, with an emphasis on treatment of HCC not amenable to surgical resection. Close attention was paid to new evidence published since the previous version of these statements in 2018.

Key Content and Findings: The expert panel has formulated 60 consensus statements to guide the staging and treatment of unresectable HCC. Since the previous version of these statements, considerable additions have been made to the recommendations on use of targeted therapies and immunotherapies because of the large volume of new evidence.

Conclusions: Our consensus statements offer guidance on how to select HCC patients for surgical or non-surgical treatment and for choosing among non-surgical modalities for patients who are not candidates for resection. In particular, there is a need for more evidence to aid physicians in the selection of second-line systemic therapies, as currently most data are limited to patients with disease progression on first-line sorafenib.


Persistent Identifierhttp://hdl.handle.net/10722/331235
ISSN
2023 Impact Factor: 6.1

 

DC FieldValueLanguage
dc.contributor.authorCheung, TT-
dc.contributor.authorYu, SCH-
dc.contributor.authorChan, SL-
dc.contributor.authorPoon, RTP-
dc.contributor.authorKwok, P-
dc.contributor.authorLee, AS-
dc.contributor.authorTai, A-
dc.contributor.authorTam, D-
dc.contributor.authorCheung, CC-
dc.contributor.authorLai, TW-
dc.contributor.authorChia, NH-
dc.contributor.authorLaw, A-
dc.contributor.authorShum, T-
dc.contributor.authorLam, YK-
dc.contributor.authorLau, V-
dc.contributor.authorLee, V-
dc.contributor.authorChong, C-
dc.contributor.authorTang, CN-
dc.contributor.authorYau, T-
dc.date.accessioned2023-09-21T06:53:56Z-
dc.date.available2023-09-21T06:53:56Z-
dc.date.issued2023-06-01-
dc.identifier.citationHepatobiliary Surgery and Nutrition, 2023, v. 12, n. 3, p. 366-385-
dc.identifier.issn2304-3881-
dc.identifier.urihttp://hdl.handle.net/10722/331235-
dc.description.abstract<p><strong>Background and Objective: </strong>Hong Kong, like many parts of Asia, faces a high burden of hepatocellular carcinoma (HCC) caused by high endemic rates of hepatitis B virus infection. Hong Kong clinicians have developed a high level of expertise in HCC treatment across surgical, transarterial, ablative, radiotherapeutic and systemic modalities. This publication summarizes the latest evidence-based recommendations on how these modalities should be used.</p><p><strong>Methods: </strong>In two meetings held in 2020, a multidisciplinary panel of surgeons, oncologists and interventional radiologists performed a narrative review of evidence on the management of HCC, with an emphasis on treatment of HCC not amenable to surgical resection. Close attention was paid to new evidence published since the previous version of these statements in 2018.</p><p><strong>Key Content and Findings: </strong>The expert panel has formulated 60 consensus statements to guide the staging and treatment of unresectable HCC. Since the previous version of these statements, considerable additions have been made to the recommendations on use of targeted therapies and immunotherapies because of the large volume of new evidence.</p><p><strong>Conclusions: </strong>Our consensus statements offer guidance on how to select HCC patients for surgical or non-surgical treatment and for choosing among non-surgical modalities for patients who are not candidates for resection. In particular, there is a need for more evidence to aid physicians in the selection of second-line systemic therapies, as currently most data are limited to patients with disease progression on first-line sorafenib.</p>-
dc.languageeng-
dc.publisherAME Publishing-
dc.relation.ispartofHepatobiliary Surgery and Nutrition-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleThe Hong Kong consensus statements on unresectable hepatocellular carcinoma: narrative review and update for 2021-
dc.typeArticle-
dc.identifier.doi10.21037/hbsn-21-405-
dc.identifier.volume12-
dc.identifier.issue3-
dc.identifier.spage366-
dc.identifier.epage385-
dc.identifier.eissn2304-389X-
dc.identifier.issnl2304-3881-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats